Pharma industry reports 105 deals worth $27 billion in September

The pharma industry reported 104 venture capital (VC) deals worth $3.5 billion in September 2021, compared to the last 12-month average (September 2020 to August 2021) of 173 deals worth $5.2 billion
Read Article

The pharma industry has reported 53 deals worth $27.5 billion as compared to the last 12-month average (September 2020 to August 2021) of 105 deals worth $27 billion in September 2021.

Merck and Company, through its subsidiary Astros Merger Sub, has agreed to acquire Acceleron Pharma Inc, a biopharmaceutical company for $180 per share in cash for an approximate total equity value of $11.5 billion; Agnafit Bidco AB to acquire all shares of Swedish Orphan Biovitrum AB (Sobi), a biopharmaceutical company for a total consideration of $8 billion; and Perrigo Co Plc to acquire Laboratoire HRA Pharma SAS for a purchase consideration of approximately $2.1 billion, were the three major deals that contributed 78.8 per cent of the total deal value during September 2021.

The pharma industry reported 104 venture capital (VC) deals worth $3.5 billion in September 2021, compared to the last 12-month average (September 2020 to August 2021) of 173 deals worth $5.2 billion.

Trialspark Inc, a tech-driven drug development company, raising $156 million, in series C funding round to acquire and/or partner on clinical-stage pharmaceutical assets to develop through their in-house clinical trial platform; Mammoth Biosciences Inc, a biotech company raising $150 million, in series D round to build next-generation CRISPR products in therapeutics and diagnostics; and Provepharm life Solutions SA, raising $142.3 million to accelerate its internal development and external growth projects, were the major VC deals reported in September 2021.

Acceleron PharmaAstros Merger SubGlobalData ReportMerck and Companypharma industry
Comments (0)
Add Comment